Article

Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar

2021-08-27

Abstract excerpt

<h4>ABSTRACT</h4> <h4>BACKGROUND</h4> Waning of vaccine protection against SARS-CoV-2 infection or COVID-19 disease is a concern. This study investigated persistence of BNT162b2 (Pfizer-BioNTech) vaccine effectiveness against infection and disease in Qatar, where the Beta and Delta variants have dominated incidence and PCR testing is done at a mass scale. <h4>METHODS</h4> A matched test-negative, case-control stud...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d42870e1-e85d-520d-8840-6c46b6f5f1d8
DOI: 10.1101/2021.08.25.21262584

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in QatarDOI 10.1101/2021.08.25.21262584Read

The Effectiveness of the First Dose of BNT162b2 Vaccine in Reducing SARS-CoV-2 Infection: Real-World EvidenceSemantic proximity Read

Waning of SARS-CoV-2 vaccine-induced immunity: A systematic review and secondary data analysisSemantic proximity Read

BNT162B2 mRNA Covid-19 Vaccine Effectiveness in the Prevention of SARS-CoV-2 Infection and Symptomatic Disease in the Medium - to Long-Term: A Retrospective Cohort StudySemantic proximity Read

The effectiveness of the first dose of BNT162b2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidenceSemantic proximity Read

Effectiveness of BNT162b2 booster doses in England: an observational study in OpenSAFELY-TPPSemantic proximity Read

Durability of protection post-primary COVID-19 vaccination in the US: matched case-control studySemantic proximity Read

Twelve-month follow-up of immunogenicity and safety of fractional and standard booster doses of the Pfizer-BioNTech COVID-19 vaccine in adults primed with ChAdOx1, BBIBP-CorV, or GAM-CoV-Vac: a randomised controlled trialSemantic proximity Read

Effectiveness of BNT162b2 mRNA COVID-19 Vaccine Against SARS-CoV-2 Variant Beta (B.1.351) Among Persons Identified Through Contact Tracing in IsraelSemantic proximity Read

Waning Effectiveness of the Third Dose of the BNT162b2 mRNA COVID-19 VaccineSemantic proximity Read

Deaths averted by vaccination due to reduced transmission can exceed those from direct protection of vaccinated individuals for SARS-CoV-2Semantic proximity Read

Effectiveness of the WHO-authorized Covid-19 Vaccines: a Rapid Review of Global Reports till June 30, 2021Semantic proximity Read

Fractional versus standard BNT162b2 boosters after non-mRNA priming in Mongolia: 24-month immunogenicity and safety evidence from a randomised controlled trialSemantic proximity Read